Truc Thanh Tran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Truc Thanh Tran has a total of 167 co-authors. Here are the top co-authors by number of shared publications:
- Cesar A. Arias
Houston Methodist Hospital
12 shared publications - William Robert Miller
Division of Infectious Diseases, Houston Methodist Hospital , Houston, Texas
11 shared publications - Samuel Shelburne
Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center
6 shared publications - Blake M. Hanson
Center for Infectious Diseases, UTHealth Houston School of Public Health, University of Texas Health Science Center at Houston
5 shared publications - Yousif Shamoo
Department of BioSciences, Rice University, Houston, Texas, USA
5 shared publications An Q. Dinh
Division of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA
4 shared publications
Latest Publications
- Open Access
- 1 April 2026
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (4) , e0178525
Reply to White and Siegrist, “Multi-drug-resistant enterococcal infections: duration of combination therapy and OPAT challenges”
- 1 April 2026
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (4) , e0178525
Open AccessReply to White and Siegrist, “Multi-drug-resistant enterococcal infections: duration of combination therapy and OPAT challenges”
- Open Access
- 10 December 2025
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 69 (12) , e0132525
Effectiveness of imipenem-relebactam for multidrug-resistant Pseudomonas aeruginosa in pneumonia and bloodstream infections in the United States (MIRAGE)
Imipenem-relebactam demonstrates in vitro activity against multidrug-resistant (MDR) Pseudomonas aeruginosa , but real-world effectiveness data are limited. MIRAGE was a multicenter, retrospective, observational study of imipenem-relebactam for MDR P. aeruginosa pneumonia and bacteremia. Patients were included if they received imipenem-relebactam for >48 h within 7 days of index P. aeruginosa culture. The primary outcome was clinical success at day 30, defined as survival, resolution of signs and symptoms of infection, completion of intended treatment course, and absence of recurrent infection. Secondary outcomes included 30- and 90-day mortality, infection recurrence, and development of non-susceptibility. Sixty-three patients were included. Median (IQR) age was 61 (51–70) years, and the median Charlson Comorbidity Index was 5 (3–6). Forty-six percent of patients had an immunocompromising condition, 79% were in the intensive care unit, 76% were receiving mechanical ventilation, and 48% required vasopressors. Median SOFA score was 7 (5–12). Forty percent of index isolates that were tested displayed non-susceptibility to both ceftolozane-tazobactam and ceftazidime-avibactam. Fifty-six percent of patients achieved clinical success at day 30. All-cause 30- and 90-day mortality rates were 18% and 29%, respectively. Recurrent infections were documented in 37% of patients within 90 days, and resistance developed in 39% (16/41) of evaluable patients. Clinical outcomes following imipenem-relebactam for treatment of MDR P. aeruginosa were comparable to those reported in real-world studies for other novel β-lactam agents. Our data suggests that imipenem-relebactam has a role in the treatment of patients infected with MDR P. aeruginosa .
- 10 December 2025
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 69 (12) , e0132525
Open AccessEffectiveness of imipenem-relebactam for multidrug-resistant Pseudomonas aeruginosa in pneumonia and bloodstream infections in the United States (MIRAGE)
Imipenem-relebactam demonstrates in vitro activity against multidrug-resistant (MDR) Pseudomonas aeruginosa , but real-world effectiveness data are limited. MIRAGE was a multicenter, retrospective, observational study of imipenem-relebactam for MDR P. aeruginosa pneumonia and bacteremia. Patients were included if they received imipenem-relebactam for >48 h within 7 days of index P. aeruginosa culture. The primary outcome was clinical success at day 30, defined as survival, resolution of signs and symptoms of infection, completion of intended treatment course, and absence of recurrent infection. Secondary outcomes included 30- and 90-day mortality, infection recurrence, and development of non-susceptibility. Sixty-three patients were included. Median (IQR) age was 61 (51–70) years, and the median Charlson Comorbidity Index was 5 (3–6). Forty-six percent of patients had an immunocompromising condition, 79% were in the intensive care unit, 76% were receiving mechanical ventilation, and 48% required vasopressors. Median SOFA score was 7 (5–12). Forty percent of index isolates that were tested displayed non-susceptibility to both ceftolozane-tazobactam and ceftazidime-avibactam. Fifty-six percent of patients achieved clinical success at day 30. All-cause 30- and 90-day mortality rates were 18% and 29%, respectively. Recurrent infections were documented in 37% of patients within 90 days, and resistance developed in 39% (16/41) of evaluable patients. Clinical outcomes following imipenem-relebactam for treatment of MDR P. aeruginosa were comparable to those reported in real-world studies for other novel β-lactam agents. Our data suggests that imipenem-relebactam has a role in the treatment of patients infected with MDR P. aeruginosa .
- Open Access
- 1 October 2025
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 69 (10) , e0106024
Therapeutic approach to difficult-to-treat multidrug-resistant enterococcal infections
Difficult-to-treat (DTR) enterococcal infections, particularly those caused by multidrug-resistant Enterococcus faecium and Enterococcus faecalis , pose significant clinical challenges due to limited treatment options and high rates of treatment failure, compounded by a paucity of new antimicrobial agents in the development pipeline. Despite advances in understanding resistance mechanisms and in vitro synergistic antibiotic combinations, robust clinical data to guide therapy for severe or DTR enterococcal infections remain limited. This review synthesizes available evidence to inform optimal management strategies, including drug selection and dosing, while highlighting areas needing further research. Given the ongoing threat posed by multidrug-resistant enterococci, we emphasize the importance of gathering robust clinical data to guide best practices for managing these difficult-to-treat infections.
- 1 October 2025
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 69 (10) , e0106024
Open AccessTherapeutic approach to difficult-to-treat multidrug-resistant enterococcal infections
Difficult-to-treat (DTR) enterococcal infections, particularly those caused by multidrug-resistant Enterococcus faecium and Enterococcus faecalis , pose significant clinical challenges due to limited treatment options and high rates of treatment failure, compounded by a paucity of new antimicrobial agents in the development pipeline. Despite advances in understanding resistance mechanisms and in vitro synergistic antibiotic combinations, robust clinical data to guide therapy for severe or DTR enterococcal infections remain limited. This review synthesizes available evidence to inform optimal management strategies, including drug selection and dosing, while highlighting areas needing further research. Given the ongoing threat posed by multidrug-resistant enterococci, we emphasize the importance of gathering robust clinical data to guide best practices for managing these difficult-to-treat infections.
- Open Access
- 22 November 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (22)
Molecular basis of cell membrane adaptation in daptomycin-resistant Enterococcus faecalis
Daptomycin is a last-resort lipopeptide antibiotic that disrupts cell membrane (CM) and peptidoglycan homeostasis. Enterococcus faecalis has developed a sophisticated mechanism to avoid daptomycin killing by redistributing CM anionic phospholipids away from the septum. The CM changes are orchestrated by a 3-component regulatory system, designated LiaFSR, with a possible contribution of cardiolipin synthase (Cls). However, the mechanism by which LiaFSR controls the CM response and the role of Cls are unknown. Here, we show that cardiolipin synthase activity is essential for anionic phospholipid redistribution and daptomycin resistance since deletion of the 2 genes ( cls1 and cls2 ) encoding Cls abolished CM remodeling. We identified LiaY, a transmembrane protein regulated by LiaFSR, and Cls1 as important mediators of CM remodeling required for redistribution of anionic phospholipid microdomains. Together, our insights provide a mechanistic framework on the enterococcal response to cell envelope antibiotics that could be exploited therapeutically.
- 22 November 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (22)
Open AccessMolecular basis of cell membrane adaptation in daptomycin-resistant Enterococcus faecalis
Daptomycin is a last-resort lipopeptide antibiotic that disrupts cell membrane (CM) and peptidoglycan homeostasis. Enterococcus faecalis has developed a sophisticated mechanism to avoid daptomycin killing by redistributing CM anionic phospholipids away from the septum. The CM changes are orchestrated by a 3-component regulatory system, designated LiaFSR, with a possible contribution of cardiolipin synthase (Cls). However, the mechanism by which LiaFSR controls the CM response and the role of Cls are unknown. Here, we show that cardiolipin synthase activity is essential for anionic phospholipid redistribution and daptomycin resistance since deletion of the 2 genes ( cls1 and cls2 ) encoding Cls abolished CM remodeling. We identified LiaY, a transmembrane protein regulated by LiaFSR, and Cls1 as important mediators of CM remodeling required for redistribution of anionic phospholipid microdomains. Together, our insights provide a mechanistic framework on the enterococcal response to cell envelope antibiotics that could be exploited therapeutically.
- 6 November 2024
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 68 (11) , e0089824
Prevalence of the cefazolin inoculum effect (CzIE) in nasal colonizing methicillin-susceptible Staphylococcus aureus in patients from intensive care units in Colombia and use of a modified rapid nitrocefin test for detection
The cefazolin inoculum effect (CzIE) has been associated with poor clinical outcomes in patients with methicillin-susceptible Staphylococcus aureus (MSSA) infections. We aimed to investigate the point prevalence of the CzIE among nasal colonizing MSSA isolates from ICU patients in a multicenter study in Colombia (2019–2023). Patients underwent nasal swabs to assess for S. aureus colonization on admission to the ICU, and some individuals had follow-up swabs. We performed cefazolin MIC by broth microdilution using standard and high inoculum and developed a modified nitrocefin-based rapid test to detect the CzIE. Whole-genome sequencing was carried out to characterize BlaZ types and allotypes, phylogenomics, and Agr-typing. A total of 352 patients were included; 46/352 (13%) patients were colonized with S. aureus and 22% (10/46) and 78% (36/46) with MRSA and MSSA, respectively. Among 36 patients who contributed with 43 MSSA colonizing isolates, 21/36 (58%) had MSSA exhibiting the CzIE. BlaZ type A and BlaZ-2 were the predominant type and allotype in 56% and 52%, respectively. MSSA belonging to CC30 were highly associated with the CzIE, and single-nucleotide polymorphism (SNP) analyses supported possible transmission of MSSA exhibiting the CzIE among some patients of the same unit. The modified nitrocefin rapid test had 100%, 94.4%, and 97.7% sensitivity, specificity, and accuracy, respectively. We found a high point prevalence of the CzIE in MSSA colonizing the nares of critically ill patients in Colombia. A modified rapid test was highly accurate in detecting the CzIE in this patient population.
- 6 November 2024
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 68 (11) , e0089824
Prevalence of the cefazolin inoculum effect (CzIE) in nasal colonizing methicillin-susceptible Staphylococcus aureus in patients from intensive care units in Colombia and use of a modified rapid nitrocefin test for detection
The cefazolin inoculum effect (CzIE) has been associated with poor clinical outcomes in patients with methicillin-susceptible Staphylococcus aureus (MSSA) infections. We aimed to investigate the point prevalence of the CzIE among nasal colonizing MSSA isolates from ICU patients in a multicenter study in Colombia (2019–2023). Patients underwent nasal swabs to assess for S. aureus colonization on admission to the ICU, and some individuals had follow-up swabs. We performed cefazolin MIC by broth microdilution using standard and high inoculum and developed a modified nitrocefin-based rapid test to detect the CzIE. Whole-genome sequencing was carried out to characterize BlaZ types and allotypes, phylogenomics, and Agr-typing. A total of 352 patients were included; 46/352 (13%) patients were colonized with S. aureus and 22% (10/46) and 78% (36/46) with MRSA and MSSA, respectively. Among 36 patients who contributed with 43 MSSA colonizing isolates, 21/36 (58%) had MSSA exhibiting the CzIE. BlaZ type A and BlaZ-2 were the predominant type and allotype in 56% and 52%, respectively. MSSA belonging to CC30 were highly associated with the CzIE, and single-nucleotide polymorphism (SNP) analyses supported possible transmission of MSSA exhibiting the CzIE among some patients of the same unit. The modified nitrocefin rapid test had 100%, 94.4%, and 97.7% sensitivity, specificity, and accuracy, respectively. We found a high point prevalence of the CzIE in MSSA colonizing the nares of critically ill patients in Colombia. A modified rapid test was highly accurate in detecting the CzIE in this patient population.
- 7 August 2024
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 68 (8) , e0012724
Cefiderocol heteroresistance associated with mutations in TonB-dependent receptor genes in Pseudomonas aeruginosa of clinical origin
The siderophore-cephalosporin cefiderocol (FDC) presents a promising treatment option for carbapenem-resistant (CR) P. aeruginosa (PA). FDC circumvents traditional porin and efflux-mediated resistance by utilizing TonB-dependent receptors (TBDRs) to access the periplasmic space. Emerging FDC resistance has been associated with loss of function mutations within TBDR genes or the regulatory genes controlling TBDR expression. Further, difficulties with antimicrobial susceptibility testing (AST) and unexpected negative clinical treatment outcomes have prompted concerns for heteroresistance, where a single lineage isolate contains resistant subpopulations not detectable by standard AST. This study aimed to evaluate the prevalence of TBDR mutations among clinical isolates of P. aeruginosa and the phenotypic effect on FDC susceptibility and heteroresistance. We evaluated the sequence of pirR , pirS , pirA , piuA , or piuD from 498 unique isolates collected before the introduction of FDC from four clinical sites in Portland, OR (1), Houston, TX (2), and Santiago, Chile (1). At some clinical sites, TBDR mutations were seen in up to 25% of isolates, and insertion, deletion, or frameshift mutations were predicted to impair protein function were seen in 3% of all isolates ( n = 15). Using population analysis profile testing, we found that P. aeruginosa with major TBDR mutations were enriched for a heteroresistant phenotype and undergo a shift in the susceptibility distribution of the population as compared to susceptible strains with wild-type TBDR genes. Our results indicate that mutations in TBDR genes predate the clinical introduction of FDC, and these mutations may predispose to the emergence of FDC resistance.
- 7 August 2024
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 68 (8) , e0012724
Cefiderocol heteroresistance associated with mutations in TonB-dependent receptor genes in Pseudomonas aeruginosa of clinical origin
The siderophore-cephalosporin cefiderocol (FDC) presents a promising treatment option for carbapenem-resistant (CR) P. aeruginosa (PA). FDC circumvents traditional porin and efflux-mediated resistance by utilizing TonB-dependent receptors (TBDRs) to access the periplasmic space. Emerging FDC resistance has been associated with loss of function mutations within TBDR genes or the regulatory genes controlling TBDR expression. Further, difficulties with antimicrobial susceptibility testing (AST) and unexpected negative clinical treatment outcomes have prompted concerns for heteroresistance, where a single lineage isolate contains resistant subpopulations not detectable by standard AST. This study aimed to evaluate the prevalence of TBDR mutations among clinical isolates of P. aeruginosa and the phenotypic effect on FDC susceptibility and heteroresistance. We evaluated the sequence of pirR , pirS , pirA , piuA , or piuD from 498 unique isolates collected before the introduction of FDC from four clinical sites in Portland, OR (1), Houston, TX (2), and Santiago, Chile (1). At some clinical sites, TBDR mutations were seen in up to 25% of isolates, and insertion, deletion, or frameshift mutations were predicted to impair protein function were seen in 3% of all isolates ( n = 15). Using population analysis profile testing, we found that P. aeruginosa with major TBDR mutations were enriched for a heteroresistant phenotype and undergo a shift in the susceptibility distribution of the population as compared to susceptible strains with wild-type TBDR genes. Our results indicate that mutations in TBDR genes predate the clinical introduction of FDC, and these mutations may predispose to the emergence of FDC resistance.
- Open Access
- 17 May 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (6) , ofae288
Clinical Features and Genomic Epidemiology of Bloodstream Infections due to Enterococcal Species Other Than Enterococcus faecalis or E. faecium in Patients With Cancer
Non–Enterococcus faecium, non–E. faecalis (NFF) enterococci are a heterogeneous group of clinically pathogenic enterococci that include species with intrinsic low-level vancomycin resistance. Patients with cancer are at increased risk for bacteremia with NFF enterococci, but their clinical and molecular epidemiology have not been extensively described. We conducted a retrospective review of all patients (n = 70) with NFF bacteremia from 2016 to 2022 at a major cancer center. The main outcomes assessed were 30-day mortality, microbiological failure (positive blood cultures for ≥4 days), and recurrence of bacteremia (positive blood culture E. gallinarum (50%) and E. casseliflavus (30%). Most (61%) patients received combination therapy. Bacteremia recurred in 4.3% of patients, there was a 30-day mortality of 23%, and 4.3% had microbiological failure. E. gallinarum and E. casseliflavus isolates were genetically diverse with no spatiotemporal clustering to suggest a single strain. Frequencies of ampicillin resistance (4.3%) and daptomycin resistance (1.9%) were low. Patients with hematologic malignancy had infections with NFF enterococci that harbored more resistance genes than patients with solid malignancy (P = .005). NFF bacteremia is caused by a heterogeneous population of isolates and is associated with significant mortality. Hematological malignancy is an important risk factor for infection with NFF resistant to multiple antibiotics.
- 17 May 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (6) , ofae288
Open AccessClinical Features and Genomic Epidemiology of Bloodstream Infections due to Enterococcal Species Other Than Enterococcus faecalis or E. faecium in Patients With Cancer
Non–Enterococcus faecium, non–E. faecalis (NFF) enterococci are a heterogeneous group of clinically pathogenic enterococci that include species with intrinsic low-level vancomycin resistance. Patients with cancer are at increased risk for bacteremia with NFF enterococci, but their clinical and molecular epidemiology have not been extensively described. We conducted a retrospective review of all patients (n = 70) with NFF bacteremia from 2016 to 2022 at a major cancer center. The main outcomes assessed were 30-day mortality, microbiological failure (positive blood cultures for ≥4 days), and recurrence of bacteremia (positive blood culture E. gallinarum (50%) and E. casseliflavus (30%). Most (61%) patients received combination therapy. Bacteremia recurred in 4.3% of patients, there was a 30-day mortality of 23%, and 4.3% had microbiological failure. E. gallinarum and E. casseliflavus isolates were genetically diverse with no spatiotemporal clustering to suggest a single strain. Frequencies of ampicillin resistance (4.3%) and daptomycin resistance (1.9%) were low. Patients with hematologic malignancy had infections with NFF enterococci that harbored more resistance genes than patients with solid malignancy (P = .005). NFF bacteremia is caused by a heterogeneous population of isolates and is associated with significant mortality. Hematological malignancy is an important risk factor for infection with NFF resistant to multiple antibiotics.
- 6 March 2024
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 68 (3) , e0106923
LiaX is a surrogate marker for cell envelope stress and daptomycin non-susceptibility in Enterococcus faecium
Daptomycin (DAP) is often used as a first-line therapy to treat vancomycin-resistant Enterococcus faecium infections, but emergence of DAP non-susceptibility threatens the effectiveness of this antibiotic. Moreover, current methods to determine DAP minimum inhibitory concentrations (MICs) have poor reproducibility and accuracy. In enterococci, DAP resistance is mediated by the LiaFSR cell membrane stress response system, and deletion of liaR encoding the response regulator results in hypersusceptibility to DAP and antimicrobial peptides. The main genes regulated by LiaR are a cluster of three genes, designated liaXYZ . In Enterococcus faecalis , LiaX is surface-exposed with a C-terminus that functions as a negative regulator of cell membrane remodeling and an N-terminal domain that is released to the extracellular medium where it binds DAP. Thus, in E. faecalis , LiaX functions as a sentinel molecule recognizing DAP and controlling the cell membrane response, but less is known about LiaX in E. faecium . Here, we found that liaX is essential in E. faecium with an activated LiaFSR system. Unlike E. faecalis , E. faecium LiaX is not detected in the extracellular milieu and does not appear to alter phospholipid architecture. We further postulated that LiaX could be used as a surrogate marker for cell envelope activation and non-susceptibility to DAP. For this purpose, we developed and optimized a LiaX enzyme-linked immunosorbent assay (ELISA). We then assessed 86 clinical E. faecium bloodstream isolates for DAP MICs and used whole genome sequencing to assess for substitutions in LiaX. All DAP-resistant clinical strains of E. faecium exhibited elevated LiaX levels. Strikingly, 73% of DAP-susceptible isolates by standard MIC determination also had elevated LiaX ELISAs compared to a well-characterized DAP-susceptible strain. Phylogenetic analyses of predicted amino acid substitutions showed 12 different variants of LiaX without a specific association with DAP MIC or LiaX ELISA values. Our findings also suggest that many E. faecium isolates that test DAP susceptible by standard MIC determination are likely to have an activated cell stress response that may predispose to DAP failure. As LiaX appears to be essential for the cell envelope response to DAP, its detection could prove useful to improve the accuracy of susceptibility testing by anticipating therapeutic failure.
- 6 March 2024
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 68 (3) , e0106923
LiaX is a surrogate marker for cell envelope stress and daptomycin non-susceptibility in Enterococcus faecium
Daptomycin (DAP) is often used as a first-line therapy to treat vancomycin-resistant Enterococcus faecium infections, but emergence of DAP non-susceptibility threatens the effectiveness of this antibiotic. Moreover, current methods to determine DAP minimum inhibitory concentrations (MICs) have poor reproducibility and accuracy. In enterococci, DAP resistance is mediated by the LiaFSR cell membrane stress response system, and deletion of liaR encoding the response regulator results in hypersusceptibility to DAP and antimicrobial peptides. The main genes regulated by LiaR are a cluster of three genes, designated liaXYZ . In Enterococcus faecalis , LiaX is surface-exposed with a C-terminus that functions as a negative regulator of cell membrane remodeling and an N-terminal domain that is released to the extracellular medium where it binds DAP. Thus, in E. faecalis , LiaX functions as a sentinel molecule recognizing DAP and controlling the cell membrane response, but less is known about LiaX in E. faecium . Here, we found that liaX is essential in E. faecium with an activated LiaFSR system. Unlike E. faecalis , E. faecium LiaX is not detected in the extracellular milieu and does not appear to alter phospholipid architecture. We further postulated that LiaX could be used as a surrogate marker for cell envelope activation and non-susceptibility to DAP. For this purpose, we developed and optimized a LiaX enzyme-linked immunosorbent assay (ELISA). We then assessed 86 clinical E. faecium bloodstream isolates for DAP MICs and used whole genome sequencing to assess for substitutions in LiaX. All DAP-resistant clinical strains of E. faecium exhibited elevated LiaX levels. Strikingly, 73% of DAP-susceptible isolates by standard MIC determination also had elevated LiaX ELISAs compared to a well-characterized DAP-susceptible strain. Phylogenetic analyses of predicted amino acid substitutions showed 12 different variants of LiaX without a specific association with DAP MIC or LiaX ELISA values. Our findings also suggest that many E. faecium isolates that test DAP susceptible by standard MIC determination are likely to have an activated cell stress response that may predispose to DAP failure. As LiaX appears to be essential for the cell envelope response to DAP, its detection could prove useful to improve the accuracy of susceptibility testing by anticipating therapeutic failure.
- Open Access
Cefiderocol heteroresistance associated with mutations in TonB-dependent receptor genes in Pseudomonas aeruginosa of clinical origin
The siderophore-cephalosporin cefiderocol(FDC) presents a promising treatment option for carbapenem-resistant (CR) P. aeruginosa (PA). FDC circumvents traditional porin and efflux mediated resistance by utilizing TonB-dependent receptors (TBDRs) to access the periplasmic space. Emerging FDC resistance has been associated with loss of function mutations within TBDR genes or the regulatory genes controlling TBDR expression. Further, difficulties with antimicrobial susceptibility testing (AST) and unexpected negative clinical treatment outcomes have prompted concerns for heteroresistance, where a single lineage isolate contains resistant subpopulations not detectable by standard AST. This study aimed to evaluate the prevalence of TBDR mutations among clinical isolates of P. aeruginosa and the phenotypic effect on FDC susceptibility and heteroresistance. We evaluated the sequence of pirR , pirS , pirA , piuA or piuD from 498 unique isolates collected before the introduction of FDC from 4 clinical sites in Portland, OR (1), Houston, TX (2), and Santiago, Chile (1). At some clinical sites, TBDR mutations were seen in up to 25% of isolates, and insertion, deletion, or frameshift mutations were predicted to impair protein function were seen in 3% of all isolates (n=15). Using population analysis profile testing, we found that P. aeruginosa with major TBDR mutations were enriched for a heteroresistant phenotype and undergo a shift in the susceptibility distribution of the population as compared to susceptible strains with wild type TBDR genes. Our results indicate that mutations in TBDR genes predate the clinical introduction of FDC, and these mutations may predispose to the emergence of FDC resistance.
Open AccessCefiderocol heteroresistance associated with mutations in TonB-dependent receptor genes in Pseudomonas aeruginosa of clinical origin
The siderophore-cephalosporin cefiderocol(FDC) presents a promising treatment option for carbapenem-resistant (CR) P. aeruginosa (PA). FDC circumvents traditional porin and efflux mediated resistance by utilizing TonB-dependent receptors (TBDRs) to access the periplasmic space. Emerging FDC resistance has been associated with loss of function mutations within TBDR genes or the regulatory genes controlling TBDR expression. Further, difficulties with antimicrobial susceptibility testing (AST) and unexpected negative clinical treatment outcomes have prompted concerns for heteroresistance, where a single lineage isolate contains resistant subpopulations not detectable by standard AST. This study aimed to evaluate the prevalence of TBDR mutations among clinical isolates of P. aeruginosa and the phenotypic effect on FDC susceptibility and heteroresistance. We evaluated the sequence of pirR , pirS , pirA , piuA or piuD from 498 unique isolates collected before the introduction of FDC from 4 clinical sites in Portland, OR (1), Houston, TX (2), and Santiago, Chile (1). At some clinical sites, TBDR mutations were seen in up to 25% of isolates, and insertion, deletion, or frameshift mutations were predicted to impair protein function were seen in 3% of all isolates (n=15). Using population analysis profile testing, we found that P. aeruginosa with major TBDR mutations were enriched for a heteroresistant phenotype and undergo a shift in the susceptibility distribution of the population as compared to susceptible strains with wild type TBDR genes. Our results indicate that mutations in TBDR genes predate the clinical introduction of FDC, and these mutations may predispose to the emergence of FDC resistance.
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
2176. Cardiolipin Synthases Play Redundant Roles And Are Required for Membrane Remodeling in Daptomycin Resistant Enterococcus faecalis
Daptomycin (DAP) is a lipopeptide antibiotic targeting anionic phospholipids (APLs) at the division septum. Resistance to DAP (DAP-R) in E. faecalis (Efs) has been associated with activation of the LiaFSR response and redistribution of APL microdomains through the effector protein LiaX. We also identified a novel transmembrane protein (designated LiaY) as essential for changes in APL microdomains which contain cardiolipin (CL). Efs encodes two CL synthase genes, cls1 and cls2. While changes in Cls1 are associated with DAP-R, their link to the LiaFSR system remains unclear. We aim to establish the roles of Cls in DAP-R to provide insights into membrane remodeling associated with DAP-R. qRT-PCR was used to study cls expression. Membrane lipid content was analyzed using hydrophilic interaction chromatography-mass spectrometry. Mutants were characterized by DAP minimum inhibitory concentration (MIC) using E-test and localization of APL microdomains with 10-N-nonyl-acridine orange. The bacterial two hybrid system was used to evaluate protein interaction. Fluorescence microscopy evaluated protein co-localization. cls1 was upregulated in DAP-R Efs OG117ΔliaX. Deletion of either cls caused upregulation of the remaining cls gene. Development of DAP-R altered membrane lipid content, namely, an increase in CL and a shift towards species with longer fatty acid chains and higher degree of unsaturation. Upon deletion of both cls, CL content was eliminated, peripheral APL microdomains were abolished, and a decrease in the DAP MIC was observed. LiaY interacted with Cls1, but not Cls2 using the two-hybrid system. The interaction was confirmed with fluorescence microscopy showing co-localization of LiaY and Cls1 at the septum and away from the septum in DAP-S and DAP-R strains, respectively. LiaY and Cls1 were also individually co-localized to APL microdomains. While Cls1 is predominantly associated with DAP-R, we show a functional redundancy between Cls1 and Cls2 in both membrane homeostasis and in DAP-R. Cls1 interacts with LiaY, which bridges the resistance mechanism with membrane adaptation, ultimately leading to altered localization of APL microdomains that divert DAP away from the division septum. William R. Miller, M.D., Merck: Grant/Research Support|UpToDate: Honoraria
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access2176. Cardiolipin Synthases Play Redundant Roles And Are Required for Membrane Remodeling in Daptomycin Resistant Enterococcus faecalis
Daptomycin (DAP) is a lipopeptide antibiotic targeting anionic phospholipids (APLs) at the division septum. Resistance to DAP (DAP-R) in E. faecalis (Efs) has been associated with activation of the LiaFSR response and redistribution of APL microdomains through the effector protein LiaX. We also identified a novel transmembrane protein (designated LiaY) as essential for changes in APL microdomains which contain cardiolipin (CL). Efs encodes two CL synthase genes, cls1 and cls2. While changes in Cls1 are associated with DAP-R, their link to the LiaFSR system remains unclear. We aim to establish the roles of Cls in DAP-R to provide insights into membrane remodeling associated with DAP-R. qRT-PCR was used to study cls expression. Membrane lipid content was analyzed using hydrophilic interaction chromatography-mass spectrometry. Mutants were characterized by DAP minimum inhibitory concentration (MIC) using E-test and localization of APL microdomains with 10-N-nonyl-acridine orange. The bacterial two hybrid system was used to evaluate protein interaction. Fluorescence microscopy evaluated protein co-localization. cls1 was upregulated in DAP-R Efs OG117ΔliaX. Deletion of either cls caused upregulation of the remaining cls gene. Development of DAP-R altered membrane lipid content, namely, an increase in CL and a shift towards species with longer fatty acid chains and higher degree of unsaturation. Upon deletion of both cls, CL content was eliminated, peripheral APL microdomains were abolished, and a decrease in the DAP MIC was observed. LiaY interacted with Cls1, but not Cls2 using the two-hybrid system. The interaction was confirmed with fluorescence microscopy showing co-localization of LiaY and Cls1 at the septum and away from the septum in DAP-S and DAP-R strains, respectively. LiaY and Cls1 were also individually co-localized to APL microdomains. While Cls1 is predominantly associated with DAP-R, we show a functional redundancy between Cls1 and Cls2 in both membrane homeostasis and in DAP-R. Cls1 interacts with LiaY, which bridges the resistance mechanism with membrane adaptation, ultimately leading to altered localization of APL microdomains that divert DAP away from the division septum. William R. Miller, M.D., Merck: Grant/Research Support|UpToDate: Honoraria